Current
Pipeline

JM-010

About JM-010

Parkinson’s disease is a common neurological disorder caused by the progressive degeneration of neurons producing dopamine. Standard of care in Parkinson’s disease is treatment with dopamine replacement therapies such as Levodopa or dopamine agonists. However, in advanced stages of Parkinson’s disease, patients treated with dopamine replacement therapies often suffer from dyskinesia, a condition that strongly impacts quality of life and in severe cases can be life-threatening. By applying the basic principles fundamental to our PRECISION MEDICINE methodology, JM-010 was developed as an innovative approach to accelerate the development of new treatment options for Parkinson’s disease patients suffering from dyskinesia.

JM-010 acts as a dual molecular switch by which the target efficacies of two existing and safe medications are perfectly fine-tuned to effectively treat the disease. Using a proprietary formulation, JM-010 targets central mechanisms underlying the development of dyskinesia in Parkinson’s disease. JM-010 has successfully demonstrated its efficacy and safety in preclinical studies, as well as in Ph1 clinical safety and Ph2 clinical proof of concept studies. Currently, JM-010 is undergoing Ph2 clinical studies in Europe and US.

CP-012

About CP-012

Levodopa is the gold-standard for treatment in Parkinson`s disease, but patients often need to administer up to 6-8 doses daily due to its short half-life and wearing-off. Since frequent dosing is not possible at nighttime, around 60% of patients suffer from disabling nocturnal and early morning muscle stiffness known as early morning akinesia. Furthermore, patients may experience a delayed onset of action with the first morning dose of Levodopa, which increases and extends their morning disability. There is currently no efficient therapy available for early morning akinesia.

We are developing CP-012 in collaboration with BDD Pharma as a novel formulation of levodopa and carbidopa to be taken ad bedtime in addition to normal medication and prevent the onset of nocturnal symptoms and early morning akinesia. Contera Pharma has full ownership and holds global rights to the program.

Neuroinflammation

About Neuroinflammation

Recent clinical and preclinical studies point towards a critical role for neuroinflammation in the development of movement disorders including Parkinson’s disease. With the University of Copenhagen, we investigate glial biology involvement in disease by utilizing state-of-the-art bioengineering tools to enable the identification of novel drug targets for us to pursue in our continued efforts to develop better treatment options for patients.

Discovery